menu
    • menu
    [{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"ETI-204","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elusys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elusys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"ETI-204","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elusys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elusys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"ETI-204","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elusys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elusys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"ETI-204","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elusys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elusys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Obiltoxaximab","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elusys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Elusys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Obiltoxaximab","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elusys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Elusys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Obiltoxaximab","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elusys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Elusys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Heat Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elusys Therapeutics \/ Heat Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Elusys Therapeutics \/ Heat Biologics"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Heat Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elusys Therapeutics \/ Heat Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Elusys Therapeutics \/ Heat Biologics"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Centers for Disease Control and Prevention | Apcer Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Raxibacumab","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elusys Therapeutics \/ Centers for Disease Control and Prevention | Apcer Life Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Elusys Therapeutics \/ Centers for Disease Control and Prevention | Apcer Life Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Elusys Therapeutics

    Menu

    Elusys Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Heat Biologics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Heat Biologics (NightHawk Biosciences) Completes Acquisition of Elusys Therapeutics

                            Details : Pursuant to this acquisition, NightHawk announced it plans to migrate manufacturing of ANTHIM® to its planned Scorpion biomanufacturing facility in Manhattan, Kansas, which is being constructed to support development of commercial-scale biologics and la...

                            Product Name : Anthim

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            April 20, 2022

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Heat Biologics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Heat Biologics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

                            Details : The strategic acquisition of Elusys is intended to enhance Heat’s immunotherapy portfolio and further position Heat to take a lead role in the biodefense space. The addition of ANTHIM (obiltoxaximab) Injection, together with Heat’s previously announc...

                            Product Name : Anthim

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            December 21, 2021

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Heat Biologics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elusys Therapeutics Receives Positive CHMP Opinion For Obiltoxaximab SFL For The Treatment Of Inhalation Anthr...

                            Details : Obiltoxaximab SFL is indicated in all age groups in combination with appropriate antibacterial drugs for the treatment of inhalational anthrax due to Bacillus anthracis; and for post-exposure prophylaxis of inhalational anthrax when alternative therapies...

                            Product Name : Anthim

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 08, 2020

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elusys Therapeutics Receives Health Canada Approval For Anthim® For The Treatment Of Inhalation Anthrax

                            Details : Health Canada has approved the company's New Drug Submission (NDS) for Anthim (obiltoxaximab for injection), the company's monoclonal antibody (mAb) anthrax antitoxin for the treatment of inhalation anthrax.

                            Product Name : Anthim

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 12, 2020

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Raxibacumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Centers for Disease Control and Prevention | Apcer Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis

                            Details : Raxibacumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Bacterial Infections.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 23, 2017

                            Lead Product(s) : Raxibacumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Centers for Disease Control and Prevention | Apcer Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETI-204

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunt...

                            Details : ETI-204 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anthrax.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 30, 2013

                            Lead Product(s) : ETI-204

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETI-204

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers

                            Details : ETI-204 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anthrax.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 30, 2013

                            Lead Product(s) : ETI-204

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETI-204

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers

                            Details : ETI-204 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anthrax.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 30, 2013

                            Lead Product(s) : ETI-204

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETI-204

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers

                            Details : ETI-204 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anthrax.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 27, 2013

                            Lead Product(s) : ETI-204

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers

                            Details : Obiltoxaximab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anthrax.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 18, 2011

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth